Portopulmonary Hypertension
Conditions
Keywords
portopulmonary hypertension, portal hypertension, esophageal or gastric varices, right heart catheterization, transpulmonary gradient, Endothelin Receptor Antagonist, Ambrisentan, Letairis, pulmonary hemodynamics
Brief summary
This is an Open Label, Multicenter, pilot clinical trial to assess the efficacy and safety of an oral selective Endothelin Receptor Antagonist (ambrisentan) in patients with portopulmonary hypertension. Preliminary evidence suggests that ambrisentan is safe and effective in patients with portopulmonary hypertension. The goal of therapy for these patients is to improve symptoms of dyspnea and to improve pulmonary hemodynamics to a mean pulmonary artery pressure \<35 mm Hg in order to make patients eligible for liver transplantation. Therefore, the primary endpoints for this study will include 6 minute walk distance (6MWD) and pulmonary vascular resistance (PVR). Eligible subjects will receive 5 mg ambrisentan once-daily for the first 4 weeks. After the initial 4-week period, investigators will increase study drug dose to 10 mg once daily (both 5 mg and 10 mg doses are FDA approved). If 10 mg is not tolerated in the opinion of investigator, then the investigator may decrease the dose back to 5 mg once daily. Primary outcome is a change in both the 6 Minute Walk Distance and in Pulmonary Vascular Resistance from baseline to Week 24. Subjects will be monitored with liver function tests (LFT) every 2 weeks for the first 8 weeks, then every 4 weeks thereafter. These safety laboratory tests may be performed at a local phlebotomy laboratory or at the Investigator clinic. In addition, the Investigator will assess each subject for safety and efficacy at Week 4, Week 12, and Week 24. Following Week 24, subjects will be assessed for safety and efficacy every 12 weeks. Patients will be followed for a total of 1 year. After 1 year, if the Investigator feels that continuing the treatment will be beneficial to the patients, they will be provided with ambrisentan by Gilead Pharmaceuticals, free of charge.
Interventions
DRUGAmbrisentan
Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
Sponsors
Gilead Sciences
Tufts Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Subjects need to fulfill all of the following 4 criteria: 1. Evidence of portal hypertension (by hemodynamic measurement, or by Doppler flow of portal circulation, or by clinical evidence of portal hypertension such as esophageal or gastric varices, as evidenced by prior upper endoscopy). 2. Evidence of pulmonary arterial hypertension by right heart catheterization (all three criteria need to be present) Right heart catheterization may have been performed up to 30 days prior to screening * Mean PAP (pulmonary artery pressure) \>25 mm Hg, and * PVR (pulmonary vascular resistance) \>240 dynes/s/cm5, and * TPG (transpulmonary gradient = meanPAP -PAWP) \>12 mm Hg 3. Baseline AST, ALT \< 5 times the upper limit of normal, total Bili \< 3.0 mg/dl, and mild liver impairment with Child -Pugh class A or B 4. Ages 18 years and above
Exclusion criteria
1. Presence of any other etiology of pulmonary arterial hypertension (HIV, connective tissue disease, sickle cell, left heart failure, chronic thromboembolic PH, etc) 2. Treatment with prostacyclins, other ERAs, or PDE5 inhibitors within 30 days of enrollment. 3. Moribund state or anticipated death within 1 month. 4. AST or ALT ≥ 5 times upper limit of normal 5. Total bilirubin ≥ 3.0 mg/dl 6. Significant lung disease (obstructive lung disease with FEV1 \< 1L, or FEV1/FVC \<50%; or restrictive lung disease with Total Lung Capacity \< 60% predicted). PFTs may have been performed up to 6 months prior to enrollment. 7. Pregnancy 8. Age \<18 years 9. Child -Pugh class C
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Pulmonary Vascular Resistance | from baseline to Week 24 | Change in Pulmonary Vascular Resistance from baseline to Week 24 for all patients (using cardiac output \[CO\] measured by the thermodilution method and reported as percent difference from baseline). |
| 6 Minute Walk Distance | Change from baseline to Week 24 | Change from baseline in 6 Minute Walk Distance to Week 24 for all patients. (difference measured in meters). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Ambrisentan (24 Weeks), Extension (4 Weeks) Long-term extension of 24-28 weeks of ambrisentan. | 30 |
| Total | 30 |
Baseline characteristics
| Characteristic | Ambrisentan (24 Weeks), Extension (4 Weeks) | — |
|---|---|---|
| Age, Categorical <=18 years | 0 Participants | — |
| Age, Categorical >=65 years | 0 Participants | — |
| Age, Categorical Between 18 and 65 years | 30 Participants | — |
| Age, Continuous | 50 years STANDARD_DEVIATION 5 | — |
| pulmonary vascular resistance | 7.1 HRU/Wood units STANDARD_DEVIATION 5 | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Region of Enrollment United States | 19 participants | — |
| Sex: Female, Male Female | 18 Participants | — |
| Sex: Female, Male Male | 12 Participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 4 / 30 |
| other Total, other adverse events | 1 / 30 |
| serious Total, serious adverse events | 14 / 30 |
Outcome results
Primary
6 Minute Walk Distance
Change from baseline in 6 Minute Walk Distance to Week 24 for all patients. (difference measured in meters).
Time frame: Change from baseline to Week 24
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ambrisentan | 6 Minute Walk Distance | Baseline | 314 meters | Standard Deviation 94 |
| Ambrisentan | 6 Minute Walk Distance | Week 24 | 336 meters | Standard Deviation 108 |
Primary
Change in Pulmonary Vascular Resistance
Change in Pulmonary Vascular Resistance from baseline to Week 24 for all patients (using cardiac output \[CO\] measured by the thermodilution method and reported as percent difference from baseline).
Time frame: from baseline to Week 24
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ambrisentan | Change in Pulmonary Vascular Resistance | 7.1 percent difference from baseline | Standard Deviation 5 |